Update on the Targeted Therapy of the Bladder Cancer

Omar Fahmy and Mohamed H Zahran

Department of Urology, University Putra Malaysia, Malaysia
Urology and Nephrology Center, Mansoura University, Egypt

^*Correspondance to: Mohamed H. Zahran 

 PDF  Full Text Review Article | Open Access

Abstract:

Bladder cancer was considered as immunogenic cancer many years ago since the detected response to BCG instillation in the bladder. Recently, utilization of check point inhibitors in malignancies is the new era in cancer immunotherapy. This novel treatment is now approved for melanomas, however in bladder cancer still in the starting phase with promising results. Many trials have been started to investigate the role of check point inhibitors in non-muscle invasive and in metastatic bladder cancer. Many efforts at the pre-clinical level suggested a role for steroid hormones in bladder cancer pathogenesis, however no available prospective data on the role of hormonal therapy in bladder cancer. In this short review we present the updates on checkpoint inhibitors in the bladder cancer and the suggested role for hormonal therapy in the future.

Keywords:

Bladder cancer; Checkpoint inhibitors; Atezolizumab; Hormonal therapy; CTLA-4

Cite the Article:

Fahmy O, Zahran MH. Update on the Targeted Therapy of the Bladder Cancer. Clin Oncol. 2016; 1: 1120.